Endostatin gene therapy - Marsala Biotech

Drug Profile

Endostatin gene therapy - Marsala Biotech

Alternative Names: Ad5-E10A; E10A

Latest Information Update: 21 Dec 2015

Price : $50

At a glance

  • Originator Guangzhou Double Bioproducts
  • Class Antineoplastics; Eye disorder therapies; Gene therapies
  • Mechanism of Action Angiogenesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Head and neck cancer

Most Recent Events

  • 10 Dec 2015 Efficacy data from a phase II trial in Head and neck cancer and Nasopharyngeal cancer (Late-stage disease, Combination therapy, Second-line therapy or greater) released by Guangzhou Double Bioproducts (NCT02630264)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top